<DOC>
	<DOCNO>NCT02934022</DOCNO>
	<brief_summary>Many patient Highly Active Antiretroviral Therapy ( HAART ) able achieve sustain response viral load become undetectable stay undetectable , increase CD4 count level great 500 . Adding maraviroc treatment regimen patient may result increase CD4 count . As patient would continue prior regimen , likely continue full control viral replication .</brief_summary>
	<brief_title>Adding Maraviroc HAART Regimen Well Controlled HIV-infected Patients</brief_title>
	<detailed_description>This prospective , open-label , non-controlled , non-randomized , single center study effect add antiretroviral Maraviroc antiretroviral treatment regimen ( HAART ) patient achieve sustained virologic response HAART sub-adequate immunologic response treatment . Patients full virologic response ( define HIV-1 viral load &lt; 48 copies/mL ) 12 month define sub-adequate immunologic response CD4 lymphocyte count go 500 . This pilot study contain 30 patient follow period 12 month start date enrollment addition maraviroc current highly active antiretroviral therapy regimen . The main outcome follow CD4 lymphocyte count baseline 12 month treatment addition maraviroc .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . HIV1 positive . 2 . Receiving highly active antiretroviral therapy ( HAART ) . 3 . HIV1 viral load &lt; 48 copy 12 month . 4 . CD4 lymphocyte count go 500 . 1 . Severe hepatic impairment ( cirrhosis ) active Hepatitis C liver transaminases &gt; 5 time normal . 2 . Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) endstage renal disease ( ESRD ) take potent CYP3A4 inhibitor inducer . 3 . Receiving certain necessary medication potential serious drugdrug interaction maraviroc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>HAART regimen</keyword>
	<keyword>Immunologic response</keyword>
</DOC>